Key result
Intravenous immunoglobulin significantly improved quality of life in patients with post-polio syndrome, but did not significantly increase muscle strength or physical performance.
Why the study?
Does intravenous immunoglobulin improve muscle strength, physical performance, and quality of life in patients with post-polio syndrome?
Does intravenous immunoglobulin improve muscle strength, physical performance, and quality of life in patients with post-polio syndrome?
IVIg may improve quality of life in patients with post-polio syndrome, though it did not significantly improve muscle strength or physical performance in this small uncontrolled pilot study.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for IVIg in post-polio syndrome; does not support practice change without randomized data.
OBJECTIVE: To analyse changes in muscle strength, physical performance and quality of life during intravenous immunoglobulin (IVIg) treatment in patients with post-polio syndrome. DESIGN: Open clinical trial. PATIENTS: A total of 14 patients (6 women, 8 men; mean age 57 years, range 43-67 years) were included in the study. INTERVENTION: Treatment with 90 g IVIg (30 g daily for 3 days). MAIN OUTCOME: Muscle strength, measured with dynamic dynamometry, muscle function, by means of performing the 6-minute walk test, and quality of life, analysed by means of the SF-36 questionnaire, were performed before and after treatment. RESULTS: For quality of life there was a statistically significant improvement for all but one of the 8 multi-item scales of SF-36 when comparing data before and after treatment with IVIg. The multi-item scale most improved was Vitality. There was no significant increase in muscle strength and physical performance. CONCLUSION: Data indicate that IVIg may have a clinically relevant effect, with an improvement in quality of life. The effect may be due to a decrease in an inflammatory process in the central nervous system, which earlier has been reported in patients with past-polio syndrome after IVIg treatment. Since a possible placebo effect cannot be ruled out, a randomized controlled study is needed.
No takes yet. Share an insight, caveat, or question.
Kaponides et al. (2006) studied post-polio syndrome (n=14). Intravenous immunoglobulin (IVIg) was evaluated on Muscle strength, muscle function (6-minute walk test), and quality of life (SF-36). Intravenous immunoglobulin significantly improved quality of life in patients with post-polio syndrome, but did not significantly increase muscle strength or physical performance.
Synapse has enriched 10 related papers. Consider them for comparative context: